By Michael Susin
Hoth Therapeutics shares rose on Tuesday after the company said early clinical data of its therapeutic HT-ALZ suggested a potential "breakthrough" in the treatment of Alzheimer's disease.
Shares in premarket trading were up nearly 15% to $1.16. On a year-to-date basis, shares are down nearly 30%.
The New York-based biopharmaceutical company said that early observations of a pre-clinical study showed that HT-ALZ treated groups of mice presented notably fewer reactive astrocytes, the drivers of neurodegenerative diseases like Alzheimer's, when compared to the vehicle-treated group.
The company said these reductions corresponded with enhanced cognitive performance, adding that these results pointed to a potential breakthrough in the treatment of Alzheimer's.
Hoth Therapeutics said it plans to continue advancing HT-ALZ through further studies and clinical trials.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 17, 2024 09:14 ET (13:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.